$KMB · KIMBERLY CLARK CORP
Kimberly-Clark completed its acquisition of Kenvue Inc. on November 2, 2026, via a two-step merger structure. Kenvue shareholders received $3.50 in cash and 0.14625 shares of KMB common stock per KVUE share. The combined company operates four segments with combined FY2025 net sales of approximately $31.6 billion and targets $2.1 billion in run-rate synergies.
- Kenvue shareholders received $3.50 cash + 0.14625 KMB shares per KVUE share; KVUE delisted from NYSE.
- Combined portfolio includes 10 billion-dollar brands: Huggies, Listerine, Cottonelle, Neutrogena, Depend, Tylenol, Kleenex, Johnson’s Baby, Kotex, Scott.
- K-C reaffirms $2.1B run-rate synergies: ~$1.9B cost synergies (3 years) + ~$500M revenue synergies, offset by ~$300M reinvestment (4 years).
- Four new business segments: North America (~$18.0B sales), EMEA (~$5.0B), Asia Pacific Focus Markets (~$4.3B), Enterprise Markets (~$4.3B).
- Three Kenvue directors joined K-C board (now 13 members); three legacy K-C directors stepped down effective immediately.
KMB down 1.89% in regular trading to $107.94 — a modest decline on a $35.90B market cap, consistent with typical acquirer pressure on deal close as integration risk reprices. The $2.1B synergy target provides a tangible value-creation roadmap that may limit downside.
This is one of the largest consumer health M&A deals in recent history, creating a $31.6B-revenue giant with 10 billion-dollar brands and a clear $2.1B synergy roadmap that will define K-C's investment thesis for years.
This deal reshapes the consumer health and wellness landscape, combining K-C's personal care dominance with Kenvue's OTC healthcare portfolio at a time when global health and wellness spending exceeds $500 billion annually. The combined entity competes directly with P&G, Unilever, and Haleon across overlapping categories.
Integration risk: $2.1B in synergies are targets, not guarantees — failure to achieve cost savings or revenue synergies on schedule would pressure returns. Substantially increased indebtedness from the acquisition and ability to maintain credit ratings are flagged as material risks. Potential goodwill and intangible asset impairment from the Kenvue acquisition could impact future results.